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We undertook this study to review the reporting of indapamide-associated electrolyte disturbances in Australia. We used chlorothiazide and the combination diuretic hydrochlorothiazide (50 mg) and amiloride hydrochloride (5 mg) as comparator drugs.
METHODS

1.Methods
The information analysed was obtained from the computerised records of Australian adverse drug reaction reports held by the Adverse Drug Reactions Advisory Committee (ADRAC). Chlorothiazide was used in Australia before the establishment of the computerised database in November 1972, and only reports received after that date were examined. The first report for the hydrochlorothiazide and amiloride combination was submitted in January 1975 and the first for indapamide in August 1984. We only considered reports in which the diuretic was the sole suspected drug.
Detailed computerised summaries of each report were retrieved, and checked against the original reports to safeguard against error during data entry. The five most commonly reported adverse reactions for each of the drugs were identified using the preferred terms from the World Health Organization Adverse Reaction Terminology. 4 There was some overlap between drugs, resulting in our analysing the 11 reactions shown in Box 1. Demographic information was extracted from each report (such details were not available in only a small number of reports) and other symptoms and signs recorded in the reports were noted.
The Royal College of Pathologists of Australasia gives the following reference intervals: Reports to ADRAC describing electrolyte disturbances do not always include laboratory results or reference intervals. For our primary analysis,
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Statistical analysis
The number of reports of each reaction as a proportion of total reports for each of the three drug products was calculated, together with the 95% confidence intervals. Two proportions were considered to be statistically significantly different if their 95% confidence intervals did not overlap.
RESULTS
1.Results
Usage data were obtained for the three diuretics (Mr Peter McManus, Pharmaceutical Benefits Branch, personal communication) by a method in which Pharmaceutical Benefits Scheme (PBS) data and results of a survey of pharmacies are combined. 6 Box 2 shows that, for the financial years 1989/90 to 1997/ 98, use of indapamide increased at a time when use of the other two drugs decreased markedly.
As shown in Box 1, 136 reports involving chlorothiazide, 390 involving the hydrochlorothiazide and amiloride combination and 401 involving indapamide had been received to 30 September 2000. Both the hydrochlorothiazide and amiloride combination and indapamide had significantly higher proportions of reports of hyponatraemia than chlorothiazide. Indapamide had a significantly higher proportion of reports of hypokalaemia than the other two drugs.
For all three drugs, at least 80% of reports of hyponatraemia were in people aged 65 For all three drugs, at least 50% of reports described patients with serum sodium concentrations р 120 mmol/L. In the 84 reports with indapamide, as well as hyponatraemia symptoms mentioned included nausea (15 reports), confusion (13), vomiting (11), dizziness (9), anorexia (8), fatigue (5), malaise (4), syncope (4), somnolence (4), headache (2) and convulsions (2) . One or more of these signs and symptoms was mentioned in 39 of the 84 reports.
At least 72 of the 84 reports of hyponatraemia with indapamide related to the use of 2.5 mg IR daily (dose explicitly stated in 53; stated as one tablet daily for a brand available only as 2.5 mg IR or reported before the 1.5 mg SR formulation was marketed in 19). Only two reports explicitly stated another daily dose. At least 77 of 87 reports of hypokalaemia with indapamide related to use of 2.5 mg IR tablets (dose explicitly stated in 59; stated as one tablet daily and reported when only 2.5 mg available in 18). Only one report explicitly stated another daily dose.
Of the 87 reports of hypokalaemia with indapamide, 35 patients also had hyponatraemia. A serum potassium concentration was included in 67 of the 87 reports (10 [15%], < 2. reports with a serum potassium concentration < 2.5 mmol/L mentioned other symptoms, including confusion, convulsions, ventricular fibrillation and syncope.
DISCUSSION
1.Discussion
Indapamide has been implicated as a cause of severe hyponatraemia in a small number of case reports, 7 and our findings support this. It is striking that there was a greater proportion of Australian reports of hyponatraemia with indapamide than with the hydrochlorothiazide and amiloride combination. Further, this proportion is many times greater than that for chlorothiazide. The reports show that indapamide-associated hyponatraemia resembles that caused by hydrochlorothiazide with amiloride in that it can be severe, and is reported predominantly in elderly women. 8 Voluntary reporting systems do not provide a basis for calculating incidence or robust estimates of risk. The experience reported here relates almost solely to 2.5 mg IR indapamide tablets, the use of which has increased in recent years. Whether similar electrolyte disturbances will be observed with 1.5 mg SR indapamide tablets, subsidised on the PBS since 1 November 2001, requires further postmarketing surveillance.
Increasing use of indapamide in place of chlorothiazide will expose more patients to the risk of hyponatraemia. Changes in the conscious or mental states in patients, especially elderly women, taking indapamide should prompt timely measurement of the serum sodium concentration.
